ArgiNOx Pharmaceuticals Inc.
This article was originally published in Start Up
Executive Summary
ArgiNOx is working on the development of drugs to modulate overproduction of nitric oxide, which has been implicated in a range of acute cardiovascular pathologies.
You may also be interested in...
StemPath Inc.
StemPath makes use of stem cells already present in tissues like the heart, for heart muscle regeneration.
Stem Cells: Heath Care's Panacea or Pariah?
The field of stem cells is still plagued by issues of ethics, efficacy, and economics.
Cellerant Therapeutics Inc.
Cellerant is a clinical-stage biotechnology company developing a portfolio of adult stem cell-derived products that could potentially regulate the hematopoietic (blood forming) system. It currently has two products in clinical development: a highly purified hematopoietic stem cell product that is a curative therapy for sickle cell disease, autoimmune diseases and cancers, and a manufactured cell product for the treatment of neutropenia in patients at risk for infection following stem cell transplant or chemotherapy.